Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.
1. Why This Matters Now Rare disease drugs now account for 52% of all new molecular entities (NMEs) approved by
Orphan Drug Reform: How Mark Cuban’s Cost-Plus Model Is Forcing a Reckoning Read Post »
A Comprehensive Industry Report regarding the Technological, Economic, and Regulatory Transformation of the Pharmaceutical Sector (2025-2030) Executive Summary: The End
How AI Is Irrevocably Altering the DNA of Drug Development Read Post »
For IP counsel, portfolio managers, R&D leads, and institutional investors who need to move faster than the competition. Why Drug
Drug Patent Searching: The Definitive Intelligence Guide for Pharma Teams Read Post »
1. The R&D Productivity Crisis: What the Numbers Actually Say The pharmaceutical industry’s core operating model has a compounding cost
Deconstructing the Middleman: Beyond the Textbook Definition To truly grasp the PBM’s role, we must look past the simple definition
PBMs, Formularies, and Rebates: What Investors Should Know Read Post »
1. The Scale of the Cliff: $236 Billion in Revenue at Risk Through 2030 The pharmaceutical industry is heading into
Generic drug companies fill more than 90% of all U.S. prescriptions and have saved the healthcare system an estimated $3.1
The Generic Drug Maker’s Escape Route: How 505(b)(2) Turns Commodities into Cash Cows Read Post »
Section 1: The Regulatory Trinity: Anatomy of the Three Small-Molecule Pathways Why the Categorization Matters More Than Most Teams Think
The 505(b)(2) Pathway: Unlocking a Hybrid Strategy for Drug Innovation Read Post »
Sign in or create a free account to read this DrugPatentWatch article
